Drugs / Donor-derived viral specific T-cells
Donor-derived viral specific T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02048332 | Feb 2014 → Jan 2027 expected | disease arising from reactivation of latent virus, disease related to hematopoietic stem cell transplant | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived viral specific T-cells | “Donor-derived viral specific T-cells (VSTs)” NCT02048332 ↗ |
| Known as | Virus-specific T cells | “Both donor-derived (DD) and third-party (TP) virus-specific T cells (VSTs) have shown efficacy and safety in viral management following HSCT in children and young adults.” PMID 36736781 ↗ Feb 2023 |
| Known as | VSTs | “donor-derived viral specific T-cells (VSTs) to treat viral infections” NCT02048332 ↗ |
| Modality | Cell therapy | “These VSTs are cells specially designed to fight the virus infections that can happen after a bone marrow transplant.” NCT02048332 ↗ |